AIIMS chief said the data of phase two and three trials of Bharat Biotech's Covaxin on 2 to 18 years age group is expected by September.
The vaccine can be available for children in India around that time following approval from the drug regulator, he said. Additionally, if the Pfizer vaccine also receives approval from the Centre then it could also become an option for children, Dr Guleria said. "If the Pfizer vaccine gets approval before that, then it can also be an option for children," the AIIMS chief said.
Yesterday, a senior government official also revealed that pharma firm Zydus Cadila is also likely to apply to the Drugs Controller General of India (DCGI) for emergency use authorisation for its Covid-19 vaccine ZyCoV-D, which